Eli Lilly and Co Newsroom

Hims & Hers, LifeMD Shares Soar 20+% Amid Novo Nordisk Deal for Weight-Loss Drugs

Barron'sApr 29 09:54 ET

Eli Lilly Stock Gets a Double Downgrade. Where Weight-Loss Drugs Go From Here. -- Barrons.com

Barron'sApr 28 12:54 ET

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

WSJjust now

ELI LILLY Earnings Preview: Recent $LLY Insider Trading, Hedge Fund Activity, and More

Quiver Quantitative17:06 ET

Sector Update: Consumer Stocks Rise in Late Afternoon

MT Newswires15:53 ET

Eli Lilly Set To Report Earnings As Investors Eye Weight Loss Drug Momentum

Benzinga13:55 ET

Eli Lilly and Company's (NYSE:LLY) P/E Still Appears To Be Reasonable

Simply Wall St12:40 ET

WW International Partners With LillyDirect Pharmacy Provider to Support Members in Getting Zepbound Vials

MT NewswiresApr 29 10:13 ET

Express News | Creyon Bio: Will Receive a $13 Mln Upfront Payment

ReutersApr 29 10:07 ET

Express News | Creyon Bio and Lilly Enter Into Rna-Targeted Oligo Therapy Development Collaboration

ReutersApr 29 10:07 ET

WeightWatchers Rises on Partnership With Eli Lilly to Enhance Zepbound Access

Seeking AlphaApr 29 10:02 ET

Hims & Hers Stock Soars. Why a Deal With Novo Nordisk for Weight-Loss Drugs Matters. -- Barrons.com

Barron'sApr 29 09:35 ET

Hims & Hers' Stock Rockets After Teaming up With Its Rival Wegovy Maker

MarketWatchApr 29 09:13 ET

Is Eli Lilly and Company (LLY) the Best Long-Term Dividend Stock to Buy According to Billionaires?

Yahoo FinanceApr 29 08:35 ET

Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100

Moomoo NewsApr 29 07:31 ET · Ratings

Wells Fargo Keeps Their Buy Rating on Eli Lilly & Co (LLY)

TipRanksApr 29 05:35 ET · Ratings

Goldman Sachs: Oral weight loss drugs will be one of the most promising new medications in recent years!

Goldman Sachs predicts that by 2030, oral weight loss drugs will account for 24% of the total weight loss drug market, and Eli Lilly and Co will lead this segment with its orforglipron. Next, pay close attention to the third-quarter results of the ATTAIN-1 trial announced by Eli Lilly, which will be the first reading of orforglipron in the field of obesity and the most important next catalyst for the oral obesity drug market.

wallstreetcnApr 28 20:47 ET

On the occasion of his first hundred days in office, Trump will hold an event at the White House to promote investment in the USA, with Company Executives from NVIDIA and other companies participating.

US government officials stated that on the 100th day of Trump's second term, over 20 senior business leaders from companies such as NVIDIA, Johnson & Johnson, Toyota, Eli Lilly and Co, and SoftBank Group will visit the White House on Wednesday to participate in an event promoting investment in the USA. A White House official mentioned that Trump plans to advocate for and promote widespread investment in the fields of USA defense, Technology, Medical Care, Consumer products, and investment Funds on the occasion of his hundredth day in office. Despite the concerns of major US enterprises regarding new tariffs, Trump is still trying to attract new investments. Airlines, aerospace companies, Auto Manufacturers, and retailers are all concerned about the impact of tariffs on USA manufacturing.

Global Market ReportApr 28 20:29 ET

Express News | Nvidia, Eli Lilly Among Ceos to Visit White House on Wednesday -Bloomberg News

ReutersApr 28 17:08 ET

US Equities Markets End Mixed Monday Ahead of Major Earnings

MT NewswiresApr 28 16:02 ET